Aspira Successfully Completes Application to the OTCQB
Aspira Women's Health Inc. (OTCQB:AWHL), an AI-enhanced bio-analytics women's health company, has completed its transition to the OTCQB markets exchange, with trading beginning on May 7, 2025. CEO Mike Buhle emphasized this move as a positive step for shareholders, highlighting the company's strategic focus on cost reduction, controlled capital raises to minimize dilution, and leveraging non-dilutive capital sources for short-term business objectives.
Aspira Women's Health Inc. (OTCQB:AWHL), un'azienda di bio-analisi per la salute femminile potenziata dall'intelligenza artificiale, ha completato il passaggio al mercato OTCQB, con l'inizio delle negoziazioni il 7 maggio 2025. Il CEO Mike Buhle ha sottolineato che questa mossa rappresenta un passo positivo per gli azionisti, evidenziando l'attenzione strategica dell'azienda sulla riduzione dei costi, raccolte di capitale controllate per minimizzare la diluizione e l'utilizzo di fonti di capitale non diluitive per gli obiettivi aziendali a breve termine.
Aspira Women's Health Inc. (OTCQB:AWHL), una empresa de bioanálisis de salud femenina potenciada por IA, ha completado su transición al mercado OTCQB, comenzando las operaciones el 7 de mayo de 2025. El CEO Mike Buhle destacó que este movimiento es un paso positivo para los accionistas, resaltando el enfoque estratégico de la compañía en la reducción de costos, levantamientos de capital controlados para minimizar la dilución y el aprovechamiento de fuentes de capital no dilutivas para los objetivos comerciales a corto plazo.
Aspira Women's Health Inc. (OTCQB:AWHL)는 AI 기반 여성 건강 바이오 분석 회사로, OTCQB 시장으로의 이전을 완료하고 2025년 5월 7일부터 거래를 시작했습니다. CEO 마이크 부흘은 이번 이동이 주주들에게 긍정적인 조치임을 강조하며, 비용 절감, 희석을 최소화하는 통제된 자본 조달, 단기 사업 목표를 위한 비희석성 자본 활용에 전략적으로 집중하고 있음을 밝혔습니다.
Aspira Women's Health Inc. (OTCQB:AWHL), une entreprise de bio-analyse de la santé des femmes améliorée par l'IA, a finalisé sa transition vers la bourse OTCQB, avec un début de cotation le 7 mai 2025. Le PDG Mike Buhle a souligné que cette démarche représente une étape positive pour les actionnaires, mettant en avant la stratégie de l'entreprise axée sur la réduction des coûts, des levées de fonds contrôlées pour minimiser la dilution, et l'exploitation de sources de capital non dilutives pour les objectifs commerciaux à court terme.
Aspira Women's Health Inc. (OTCQB:AWHL), ein KI-gestütztes Bio-Analytics-Unternehmen im Bereich Frauengesundheit, hat den Übergang zur OTCQB-Börse abgeschlossen, der Handel begann am 7. Mai 2025. CEO Mike Buhle betonte, dass dieser Schritt ein positiver Fortschritt für die Aktionäre sei und hob den strategischen Fokus des Unternehmens auf Kostensenkung, kontrollierte Kapitalerhöhungen zur Minimierung der Verwässerung sowie die Nutzung nicht-verwässernder Kapitalquellen für kurzfristige Geschäftsziele hervor.
- Strategic focus on cost reduction initiatives
- Controlled approach to capital raises to minimize dilution
- Utilization of non-dilutive funding sources
- Downgrade from major exchange to OTCQB market indicates potential financial or compliance issues
- Trading on OTCQB typically means reduced liquidity and visibility compared to major exchanges
- May face challenges attracting institutional investors due to OTC status
AUSTIN, TX / ACCESS Newswire / May 7, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering the leading tools critical to gynecologic disease diagnostics and disease management, today announced it has successfully completed the process of transitioning to the OTCQB markets exchange. The Company begins trading on the OTCQB marketplace today, May 7, 2025.
"This is a positive next step for Aspira and our shareholders," commented Mike Buhle, CEO of Aspira. "Our decision to prioritize OTCQB was carefully considered for the benefit of our current and future shareholders. We have focused heavily on cost reduction, tactically executing smaller capital raises that target controlling dilution effects and levering non-dilutive sources of capital to fund our short-term business objectives. We are optimistic that as we continue to execute our milestones, we can continue to unlock meaningful value for shareholders. Moving to the OTCQB is an important and valuable part of our commitment to our shareholders."
About Aspira Women's Health Inc.
Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases. OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year.
OvaWatch provides a negative predictive value of
Our in-development test pipeline will expand our ovarian cancer portfolio and address the tremendous need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, we intend to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, we have developed the first-ever non-invasive test designed to identify endometriomas, one of the most commonly occurring forms of severe endometriosis. Through our ongoing endometriosis development program, we are combining microRNA and protein biomarkers with patient data, with the intent of identifying all endometriosis independent of disease location or severity.
Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the development pipeline and other statements that are predictive in nature, and whether the marketing of the OvaSuite portfolio will prove successful. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "designed to," "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," and other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission (SEC), including those factors identified as "Risk Factors" in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira's expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company's assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira's assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor Relations Contact:
SOURCE: Aspira Women's Health
View the original press release on ACCESS Newswire
FAQ
Why did Aspira Women's Health (AWHL) move to OTCQB market?
What does trading on OTCQB mean for AWHL shareholders?
When did Aspira Women's Health (AWHL) begin trading on OTCQB?
What is Aspira Women's Health's (AWHL) business focus?
